FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Liu, Keng-Yu	Mediastinum germ cell tumor	29 Mar 2022
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1326257-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Mediastinum germ cell tumor
NAME Liu, Keng-Yu
DATE OF BIRTH 10 December 1997
SEX Male
MEDICAL RECORD # 43405294

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Mediastinum
SPECIMEN ID 21-3597 A6 (N125933495 PF040)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 21 January 2021
SPECIMEN RECEIVED 21 March 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS A146V
PTEN P213fs*8
SDHB Q164*
TP53 G245C

Report Highlights

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 7)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 0 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***KRAS* -** A146V	none	none
10 Trials *see p. 7*		
***PTEN* -** P213fs*8	none	none
10 Trials *see p. 9*		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI positivity at any level has been reported in 0-31% (n = 17-188) of testicular germ cell tumors (GCTs)[6-14] and in 33% (12/36) of ovarian GCTs[9]. Within testicular GCTs, 12-31% of cases (n = 17-51) have been classified as having low-level MSI (MSI-L) and 69-100% (n = 17-133) have been classified as MSS[10,12,14], with MSI-high (MSI-H) rarely reported; one study identified MSI-L in 6% (6/100) and MSI-H in 0% (0/100) of unselected testicular GCTs, and MSI-L in 6% (2/35) and MSI-H in 26% (9/35) of chemotherapy-resistant cases[15-16]. The significance of MSI in the context of GCTs is not well established (PubMed, Nov 2021). One study reported MSI-H to be significantly more frequent in chemotherapy-resistant than unselected testicular GCT cases[15-16], and some studies have associated MSI positivity with reduced PFS and/or increased risk of recurrence[11,15-17]; however, another study found no correlation between MSI status and clinicopathologic features, including chemotherapy sensitivity and outcome[12].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[18]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[18-20]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[21-23]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[18,20,22-23].

BIOMARKER

Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[24-26], anti-PD-1 therapies[24-27], and combination nivolumab and ipilimumab[28-33]. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors[24-27,34]. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors[24]. Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy[35] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[25]. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials[27,34]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Compared to other tumor types, germ cell tumors (GCTs) have been reported to have a low TMB (mean 0.51 mutations per megabase [muts/Mb] as measured in tissue), with a similar mutation rate reported for seminoma (0.50 muts/Mb) and non-seminoma (0.49 muts/Mb) tumors[36]. Published data investigating the prognostic implications of TMB in germ cell tumors are limited (PubMed, Sep 2021).

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[37-38] and cigarette smoke in lung cancer[39-40], treatment with temozolomide-based chemotherapy in glioma[41-42], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[43-47], and microsatellite instability (MSI)[43,46-47]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[25-26,34].

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
KRAS

ALTERATION
A146V

TRANSCRIPT ID
NM_004985

CODING SEQUENCE EFFECT
437C>T

VARIANT ALLELE FREQUENCY (% VAF)
58.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[48-53]. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[54]. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated low-grade serous ovarian cancer and 12% (2/17) for patients with KRAS-mutated non-small cell lung cancer (NSCLC) in a Phase 1 study[55-56] . Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[57-58]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[59]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[60]. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors[61-62]. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations[63-64] . While clinical responses have been reported for patients with KRAS-mutated ovarian[65-68], cervical small cell neuroendocrine[69], or uterine cancer[67] treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS-altered tumors including KRAS-mutated CRC[70-73], pancreatic cancer[74-76], and NSCLC[71,77-78]. A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS-mutated (2/2 SDs) or KRAS-amplified (1/1 SD) cancer[79]. Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS-mutated ovarian cancer[80-82] and KRAS-mutated endometrioid adenocarcinoma[83].

FREQUENCY & PROGNOSIS

KRAS in germ cell neoplasms has been most extensively studied in the context of testicular germ cell tumors. KRAS amplification and mutation have been observed in 6.3-30% and 0.0-40% of testicular germ cell tumors, respectively (cBioPortal, Feb 2022)[84-89]. KRAS mutations have been infrequently reported in ovarian germ cell tumors, but have been identified in malignant tumors arising from teratomas[90-92]. KRAS amplification and mutation have been linked to invasive growth of testicular germ cell tumors but were found not to provide predictive information regarding response to therapy and patient survival[16,93-94].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[49,95]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic[49,96-118].

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
PTEN

ALTERATION
P213fs*8

TRANSCRIPT ID
NM_000314

CODING SEQUENCE EFFECT
638delC

VARIANT ALLELE FREQUENCY (% VAF)
72.0%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[119-122]. Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K-AKT-mTOR pathway. However, limited studies in prostate cancer[123-126], renal cell carcinoma[127], breast cancer[128-129], and colorectal cancer[130] have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K-AKT-mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[131-135], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[136], ovarian cancer[137], uterine leiomyosarcoma[138], and endometrial cancer[135] treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[139-140].

FREQUENCY & PROGNOSIS

PTEN mutations have been reported in <1% of 459 testicular and 1.6% of 63 ovarian germ cell tumors analyzed in the COSMIC database (Dec 2021)[141]. Mediastinum germ cell tumors commonly manifest in adult male patients as testicular germ cell tumors (TGCT). PTEN loss and subsequent activation of the AKT pathway has been observed to be common in TGCT, through PTEN mutation or loss of heterozygosity[142-144]. Loss of PTEN has been associated with the development of germ cell tumors in numerous studies[145-147]. One study examining PTEN expression in 60 germ cell tumors and adjacent precancerous lesions found that PTEN expression was present in all normal cells and precancerous lesions, but absent from 56-100% of germ cell tumors. The authors suggest that PTEN loss is therefore a late event in the development of germ cell tumors[143]. A case study reported somatic mutation of PTEN and TP53 in a patient with concurrent extragonadal germ cell tumor and acute megakaryoblastic leukemia[148]. Published data investigating the prognostic implications of PTEN alteration in germ cell tumors are limited (PubMed, Mar 2022).

FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[120]. Alterations such as seen here may disrupt PTEN function or expression[149-190].

POTENTIAL GERMLINE IMPLICATIONS

PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[191-192]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[191,193]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[191]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
SDHB

ALTERATION
Q164*

TRANSCRIPT ID
NM_003000

CODING SEQUENCE EFFECT
490C>T

VARIANT ALLELE FREQUENCY (% VAF)
45.6%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies available to directly target the loss or inactivation of SDH genes. Preclinical studies have shown that succinate, which can accumulate as a result of SDH inactivation, promotes angiogenesis via VEGF upregulation[194-195]. Case studies have reported objective responses in patients with renal cell carcinoma harboring either SDHA or SDHC alterations treated with multikinase inhibitors that target VEGFR, including sunitinib and pazopanib[196-197]; however, these clinical data are limited. In a Phase 2 trial of vandetanib for children and adults with gastrointestinal stromal tumors (GISTs) with decreased SDH expression that were wild-type for KIT and PDGFRA, no partial or complete responses were observed and 2/9 patients experienced prolonged stable disease[198].

FREQUENCY & PROGNOSIS

Somatic mutations in SDHB are rare and have been observed in fewer than 2% of tumors across all cancer types (COSMIC, 2022)[141]. SDH deficiency has been associated with an aggressive subset of renal cell carcinoma with distinctive clinical and morphological features, affecting mostly younger patients[199-202].

FINDING SUMMARY

SDHB encodes the succinate dehydrogenase complex, subunit B, flavoprotein. This protein is involved in the mitochondrial respiratory chain. SDH deficiency due to germline inactivating mutations in SDH genes is associated with paraganglioma–pheochromocytoma syndrome (PGL/PCC), Leigh syndrome, and gastrointestinal stromal tumors (GIST), which typically do not harbor mutations in KIT or PDGFRA and are not sensitive to treatment with imatinib[203-206].

POTENTIAL GERMLINE IMPLICATIONS

In the context of hereditary paraganglioma-pheochromocytoma, SDHB mutations are autosomal dominant[207] and associated with an increased risk of developing malignant and metastatic disease[208-209]. SDHB has an increased malignancy risk compared with that of SDHC or SDHD mutation[210]. In the appropriate clinical context, germline testing of SDHB is recommended.

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
G245C

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
733G>T

VARIANT ALLELE FREQUENCY (% VAF)
76.0%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[211-214], or p53 gene therapy and immunotherapeutics such as SGT-53[215-219] and ALT-801[220]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[221]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[222]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[223]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[80]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[224]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[225]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[226]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[219]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[227-229]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[230]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[231-232]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[233-234]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 34% (27/79) of ovarian germ cell tumors (GCTs) and in 3.8% of testicular GCTs analyzed in COSMIC (Nov 2021). One study identified TP53 mutations in 18.0% (9/50) of patients with metastatic GCTs, all cisplatin resistant[235]. Expression of p53 has been detected in 62% (33/53) of ovarian and testicular GCTs in one study, while low expression of p53 has been reported in 14% (3/22) of ovarian GCTs in a separate study[236-237]. In addition, expression of p53 has been frequently observed in testicular GCTs, with an incidence of 51% (56/109) to 94% (142/151) and a higher incidence in nonseminomatous GCTs compared with seminomas[238-240]. Elevated p53 protein expression, which is indicative of TP53 dysregulation, did not significantly correlate with metastasis of seminomas[238] or non-seminomas[241-243].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[244]. Alterations such as seen here may disrupt TP53 function or expression[245-249].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2021)[250]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[251-253], including sarcomas[254-255]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[256] to 1:20,000[255]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[257]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[258-263]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[258-259]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[264]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[262,265-266]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
KRAS

ALTERATION
A146V

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors.

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03284502

PHASE 1

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

TARGETS
MEK, RAFs

LOCATIONS: Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas

NCT02079740

PHASE 1/2

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

TARGETS
BCL2, BCL-XL, BCL-W, MEK

LOCATIONS: Massachusetts

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04720976

PHASE 1/2

JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

TARGETS
MEK, SHP2, PD-1, EGFR, KRAS

LOCATIONS: Utah

NCT04965818

PHASE 1/2

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

TARGETS
MEK, FGFRs

LOCATIONS: California, Indiana, Texas

NCT04800822

PHASE 1

PF-07284892 in Participants With Advanced Solid Tumors

TARGETS
SHP2, ROS1, ALK, MEK, BRAF, EGFR

LOCATIONS: California, Michigan, New York, Tennessee, Texas

NCT02407509

PHASE 1

Phase I Trial of RO5126766

TARGETS
RAFs, MEK, mTOR

LOCATIONS: London (United Kingdom), Sutton (United Kingdom)

NCT04683354

PHASE 1

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

TARGETS
MEK

LOCATIONS: Nevada, California, Ohio, Tennessee, Texas

GENE
PTEN

ALTERATION
P213fs*8

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)

NCT04001569

PHASE 1/2

AZD8186 and Paclitaxel in Advanced Gastric Cancer

TARGETS
PI3K-beta

LOCATIONS: Seongnam-si (Korea, Republic of)

NCT05035745

PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04632992

PHASE 2

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, PD-L1, ERBB2, PI3K-alpha, RET, AKTs

LOCATIONS: Alaska, Washington, Oregon, California, Idaho

NCT04770246

PHASE 2

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

TARGETS
AKT2, AKT1, AKT3

LOCATIONS: Vienna (Austria), London (United Kingdom), Villejuif (France), California, Ohio, Pennsylvania, Texas

NCT03994796

PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Washington, Oregon, Idaho, Montana

NCT03830918

PHASE 1/2

Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

TARGETS
PARP

LOCATIONS: California

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CTNNB1
amplification

DIS3
I619V

FGFR3
G44S

MLH1
amplification

MST1R
amplification

MYD88
amplification

NOTCH1
A1448S

PPARG
amplification

PTCH1
R1342H

RAF1
amplification

SETD2
amplification

TGFBR2
amplification

TSC1
Q654E

VHL
amplification

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV1*
ETV4	*ETV5*	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*
KMT2A (MLL)	*MSH2*	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*
RAF1	*RARA*	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***
TMPRSS2								

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 6.1.0

The median exon coverage for this sample is 491x

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Lothe RA, et al. Cancer Res. (1993) pmid: 8261392
7. Murty VV, et al. Cancer Res. (1994) pmid: 8033127
8. Huddart RA, et al. Br. J. Cancer (1995) pmid: 7669575
9. Faulkner SW, et al. Gynecol. Oncol. (2000) pmid: 11006028
10. Devouassoux-Shisheboran M, et al. Mol. Hum. Reprod. (2001) pmid: 11719586
11. Velasco A, et al. Cancer Biol. Ther. (2004) pmid: 15492498
12. Olasz J, et al. Anticancer Res. () pmid: 16309235
13. Vladušić T, et al. Anticancer Res. (2014) pmid: 25075023
14. Cárcano FM, et al. Andrology (2016) pmid: 27153176
15. Mayer F, et al. Cancer Res. (2002) pmid: 12019150
16. Honecker F, et al. J. Clin. Oncol. (2009) pmid: 19289622
17. Velasco A, et al. Int. J. Cancer (2008) pmid: 18076065
18. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
19. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
20. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
21. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
22. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
23. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
24. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
25. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
26. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
27. Cristescu R, et al. Science (2018) pmid: 30309915
28. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
29. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
30. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
31. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
32. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
33. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
34. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
35. Legrand et al., 2018; ASCO Abstract 12000
36. Litchfield K, et al. Nat Commun (2015) pmid: 25609015
37. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
38. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
39. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
40. Rizvi NA, et al. Science (2015) pmid: 25765070
41. Johnson BE, et al. Science (2014) pmid: 24336570
42. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
43. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
44. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
45. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
46. Nature (2012) pmid: 22810696
47. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
48. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
49. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
50. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
51. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
52. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
53. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
54. Guo C, et al. Lancet Oncol (2020) pmid: 33128873
55. Krebs et al., 2021; AACR Abstract CT019
56. Shinde et al., 2020; AACR Abstract CT143
57. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
58. Mainardi S, et al. Nat Med (2018) pmid: 29808006
59. Koczywas et al., 2021; AACR Abstract LB001
60. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
61. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722
62. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
63. Hofmann et al., 2021; AACR Abstract CT210
64. Gort et al., 2020; ASCO Abstract TPS3651
65. Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286
66. Farley J, et al. Lancet Oncol. (2013) pmid: 23261356
67. Slosberg ED, et al. Oncotarget (2018) pmid: 29765547
68. Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554
69. Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998
70. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
71. Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927
72. Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139
73. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
74. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
75. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
76. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
77. Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381
78. Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668
79. Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140
80. Spreafico et al., 2014; ASCO Abstract 5506
81. Juric et al., 2014; ASCO Abstract 9051
82. Banerji et al., 2014; ASCO Abstract e13559
83. Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608
84. Bagrodia A, et al. J. Clin. Oncol. (2016) pmid: 27646943
85. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
86. Gao J, et al. Sci Signal (2013) pmid: 23550210
87. Goddard NC, et al. Int. J. Androl. (2007) pmid: 17573850
88. McIntyre A, et al. Neoplasia (2005) pmid: 16354586
89. Moul JW, et al. Genes Chromosomes Cancer (1992) pmid: 1381946
90. Li Y, et al. J Ovarian Res (2014) pmid: 25297496
91. Hershkovitz D, et al. Pathol. Int. (2013) pmid: 24422958
92. Stanojevic B, et al. BMC Cancer (2012) pmid: 22682753
93. Mayer F, et al. BJU Int. (2011) pmid: 20955261
94. Roelofs H, et al. Am. J. Pathol. (2000) pmid: 11021820
95. Kahn S, et al. Anticancer Res. () pmid: 3310850
96. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
97. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
98. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
99. Sci. STKE (2004) pmid: 15367757
100. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
101. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
102. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
103. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
104. Kim E, et al. Cancer Discov (2016) pmid: 27147599
105. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
106. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
107. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
108. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
109. Scheffzek K, et al. Science (1997) pmid: 9219684
110. Scholl C, et al. Cell (2009) pmid: 19490892
111. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
112. Tyner JW, et al. Blood (2009) pmid: 19075190
113. Valencia A, et al. Biochemistry (1991) pmid: 2029511
114. White Y, et al. Nat Commun (2016) pmid: 26854029
115. Wiest JS, et al. Oncogene (1994) pmid: 8058307
116. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
117. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
118. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
119. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
120. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
121. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
122. Milella M, et al. Sci Rep (2017) pmid: 28220839
123. Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881
124. Sweeney C, et al. Lancet (2021) pmid: 34246347
125. de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818
126. Saura C, et al. Cancer Discov (2017) pmid: 27872130
127. Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302
128. André F, et al. J. Clin. Oncol. (2016) pmid: 27091708
129. Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354
130. Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599
131. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
132. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
133. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
134. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
135. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
136. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
137. Dougherty et al., 2014; ASCO Abstract 5536
138. Pan M, et al. Perm J (2021) pmid: 33970096
139. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
140. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
141. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
142. Oosterhuis JW, et al. Nat. Rev. Cancer (2005) pmid: 15738984
143. Di Vizio D, et al. Oncogene (2005) pmid: 15674339
144. Teng DH, et al. Cancer Res. (1997) pmid: 9393738
145. Hennenlotter J, et al. Anticancer Res. (2011) pmid: 22110200
146. Kimura T, et al. Development (2003) pmid: 12620992
147. Di Cristofano A, et al. Nat. Genet. (1998) pmid: 9697695
148. Oshrine BR, et al. Cancer Genet (2014) pmid: 24831771
149. Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747
150. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076
151. He X, et al. Cancer Res. (2013) pmid: 23475934

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

152. Han SY, et al. Cancer Res. (2000) pmid: 10866302
153. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831
154. Pradella LM, et al. BMC Cancer (2014) pmid: 24498881
155. Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651
156. Denning G, et al. Oncogene (2007) pmid: 17213812
157. Hlobilkova A, et al. Anticancer Res. () pmid: 16619501
158. Redfern RE, et al. Protein Sci. (2010) pmid: 20718038
159. Shenoy S, et al. PLoS ONE (2012) pmid: 22505997
160. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485
161. Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519
162. Lee JO, et al. Cell (1999) pmid: 10555148
163. Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567
164. Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913
165. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241
166. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331
167. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
168. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
169. Liu J, et al. Oncogene (2014) pmid: 23995781
170. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
171. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691
172. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
173. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
174. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
175. Gil A, et al. PLoS ONE (2015) pmid: 25875300
176. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
177. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
178. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
179. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
180. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
181. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
182. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
183. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
184. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
185. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
186. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
187. Wang X, et al. Biochem. J. (2008) pmid: 18498243
188. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
189. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
190. Shan L, et al. Cell Discov (2020) pmid: 32704382
191. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
192. Orloff MS, et al. Oncogene (2008) pmid: 18794875
193. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
194. Mu X, et al. Oncotarget (2017) pmid: 28061458
195. Selak MA, et al. Cancer Cell (2005) pmid: 15652751
196. McEvoy et al., 2018; doi:10.1038/s41698-018-0053-2
197. Shuch B, et al. J. Clin. Oncol. (2016) pmid: 25024072
198. Glod J, et al. Clin. Cancer Res. (2019) pmid: 31439578
199. Paik JY, et al. J. Clin. Oncol. (2014) pmid: 24395865
200. Williamson SR, et al. Mod. Pathol. (2015) pmid: 25034258
201. Ricketts CJ, et al. J. Urol. (2012) pmid: 23083876
202. van Nederveen FH, et al. Lancet Oncol. (2009) pmid: 19576851
203. Tirumani SH, et al. Br J Radiol (2014) pmid: 25189191
204. Hoekstra AS, et al. Biochim. Biophys. Acta (2013) pmid: 23174333
205. Belinsky MG, et al. Front Oncol (2013) pmid: 23730622
206. Renkema GH, et al. Eur. J. Hum. Genet. (2015) pmid: 24781757
207. Hensen EF, et al. Oncogene (2004) pmid: 15064708
208. van Hulsteijn LT, et al. J. Med. Genet. (2012) pmid: 23099648
209. Lenders JWM, et al. Endocrinol Metab (Seoul) (2017) pmid: 28685506
210. Benn DE, et al. Endocr. Relat. Cancer (2015) pmid: 26273102
211. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
212. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
213. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
214. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
215. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
216. Xu L, et al. Mol. Med. (2001) pmid: 11713371
217. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
218. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
219. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
220. Hajdenberg et al., 2012; ASCO Abstract e15010
221. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
222. Moore et al., 2019; ASCO Abstract 5513
223. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
224. Lee J, et al. Cancer Discov (2019) pmid: 31315834
225. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
226. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
227. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
228. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
229. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
230. Gourley et al., 2016; ASCO Abstract 5571
231. Kwok M, et al. Blood (2016) pmid: 26563132
232. Boudny M, et al. Haematologica (2019) pmid: 30975914
233. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
234. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
235. Cheng ML, et al. JCO Precis Oncol (2020) pmid: 33163850
236. Soini Y, et al. Hum. Pathol. (1996) pmid: 8912834
237. Liu FS, et al. Cancer (1995) pmid: 8625105
238. Gallegos I, et al. Appl. Immunohistochem. Mol. Morphol. (2011) pmid: 20881837
239. García-Velasco A, et al. Clin Transl Oncol (2012) pmid: 22634534
240. Heidenreich A, et al. APMIS (1998) pmid: 9524567
241. Albers P, et al. Mod. Pathol. (1995) pmid: 7545814
242. Lewis DJ, et al. J. Urol. (1994) pmid: 8015085
243. Ulbright TM, et al. Mod. Pathol. (1994) pmid: 7909155
244. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
245. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
246. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
247. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
248. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
249. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
250. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
251. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
252. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
253. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
254. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
255. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
256. Lalloo F, et al. Lancet (2003) pmid: 12672316
257. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
258. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
259. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
260. Xie M, et al. Nat. Med. (2014) pmid: 25326804
261. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
262. Severson EA, et al. Blood (2018) pmid: 29678827
263. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
264. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
265. Chabon JJ, et al. Nature (2020) pmid: 32269342
266. Razavi P, et al. Nat. Med. (2019) pmid: 31768066

Electronically signed by Vamsi Parimi, M.D., M.P.H. | 29 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531